Viking Therapeutics Inc. (VKTX) Has Surged To A New High On Study Results

Viking Therapeutics Inc. (VKTX) announced Tuesday morning that its Phase 2 study of VK2809, in patients with non-alcoholic fatty liver disease, achieved its primary endpoint.

from RTT - Hot Stocks https://ift.tt/2xtUtZv
via IFTTT